BBB

R&D

Oligo therapies are emerging as promising therapeutics with the potential to address previously untreatable conditions.

News

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.